Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project

Autor:	Alison J. Moskowitz, Oliver Sartor, Charles L. Bennett, Alain H. Rook, Thomas Coyne, Gloria von Geldern, Craig H. Moskowitz, Ellen J. Kim, Alison W. Loren, Dennis W. Raisch, Scott D. Newsome, LeAnn B. Norris, Donald E. Tsai, Nina D. Wagner-Johnston, Kenneth R. Carson, Daniel J. Landsburg, P. Brandon Bookstaver, Pankaj Jalan
Rok vydání:	2014
Předmět:	Oncology Cancer Research medicine.medical_specialty Mycosis fungoides Pathology business.industry Network on Progressive multifocal leukoencephalopathy medicine.disease Lymphoma Immune system Internal medicine Product Label Monoclonal medicine business Brentuximab vedotin medicine.drug
Zdroj:	Cancer. 120:2464-2471
ISSN:	0008-543X
Popis:	Purpose Brentuxiumab vedotin (BV) is an anti-CD30 monoclonal antibody-drug conjugate approved in 2011 for treating anaplastic large cell and Hodgkin lymphomas. The product label indicates that three BV-treated patients developed progressive multifocal leukoencephalopathy (PML), a frequently fatal JC-virus induced central nervous system infection. Prior immunosuppressive therapy and compromised immune systems were postulated risk factors. We report 5 patients who developed BV-associated PML, including two immunocompetent patients.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c3134d2b2ed004456547c5327e9937ae https://doi.org/10.1002/cncr.28712 Zobrazit plný text záznamu Plný text